129 related articles for article (PubMed ID: 37903733)
1. Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.
Pozorski V; Park Y; Mohamoud Y; Tesfamichael D; Emamekhoo H; Birbrair A; Albertini MR; Ma VT
Pigment Cell Melanoma Res; 2023 Nov; 36(6):501-511. PubMed ID: 37903733
[TBL] [Abstract][Full Text] [Related]
2. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
3. Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.
Gil L; Alves FR; Silva D; Fernandes I; Fontes-Sousa M; Alves M; Papoila A; Da Luz R
Cureus; 2022 Feb; 14(2):e22224. PubMed ID: 35340486
[TBL] [Abstract][Full Text] [Related]
4. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
5. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Zhuang TZ; Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2023 Mar; 28(3):239-245. PubMed ID: 36427017
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.
Ye M; Huang A; Yuan B; Tan G; Ai J; Liu H
Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):1971-1989. PubMed ID: 38315178
[TBL] [Abstract][Full Text] [Related]
7. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.
Nakamura Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M; Fujisawa Y
Jpn J Clin Oncol; 2019 May; 49(5):431-437. PubMed ID: 30753621
[TBL] [Abstract][Full Text] [Related]
8. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Tucker MD; Brown LC; Chen YW; Kao C; Hirshman N; Kinsey EN; Ancell KK; Beckermann KE; Davis NB; McAlister R; Schaffer K; Armstrong AJ; Harrison MR; George DJ; Rathmell WK; Rini BI; Zhang T
Biomark Res; 2021 Nov; 9(1):80. PubMed ID: 34732251
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
11. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis.
Ma Y; Ma X; Wang J; Wu S; Wang J; Cao B
World J Surg Oncol; 2022 Jul; 20(1):242. PubMed ID: 35897018
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
[TBL] [Abstract][Full Text] [Related]
13. Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Suzuki S; Abe T; Endo T; Kaya H; Kitabayashi T; Kawasaki Y; Yamada T
Cancer Manag Res; 2022; 14():3293-3302. PubMed ID: 36452436
[TBL] [Abstract][Full Text] [Related]
14. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
Sacdalan DB; Lucero JA; Sacdalan DL
Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
Gambale E; Maruzzo M; Messina C; De Gennaro Aquino I; Vascotto IA; Rossi V; Bimbatti D; Cavasin N; Messina M; Mennitto A; Rebuzzi SE; Nasso C; Mercinelli C; Maiorano BA; Fanelli M; Sorarù M; Scolari F; Mela MM; Galli L; Salfi A; Rizzo M; Puglisi S; Orlando V; Fornarini G; Rametta A; Giannatempo P; Cerbone L; Doni L; Roviello G; Pillozzi S; Antonuzzo L
Clin Genitourin Cancer; 2024 Aug; 22(4):102099. PubMed ID: 38776583
[TBL] [Abstract][Full Text] [Related]
20. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-
Bai X; Dai J; Li C; Cui C; Mao L; Wei X; Sheng X; Chi Z; Yan X; Tang B; Lian B; Wang X; Zhou L; Li S; Kong Y; Qi Z; Xu H; Duan R; Guo J; Si L
Front Oncol; 2021; 11():639085. PubMed ID: 34094921
[No Abstract] [Full Text] [Related]
[Next] [New Search]